Adamax
Adamax is a Russian-developed synthetic peptide neuroregulator, structurally derived from a brain peptide and sharing chemistry with the broader Russian neuropeptide family (Selank, Semax, Cortagen, Cortexin). Specifically: Adamax is a tetra/heptapeptide with anxiolytic, neurotrophic, and modest cognitive effects in Russian Federation research settings. Limited Western clinical literature; available as a research chemical primarily through Russian and Eastern European peptide suppliers.
Starting dose. 100-200mcg — Per nostril
Intranasal application morning and/or pre-stress event. Reconstitute with bac water for nasal solution; refrigerate.
Start here. Every protocol below is ordered lowest-first. Begin at the smallest effective dose, hold about a week to assess tolerance, and step up only if needed.
How it works
Adamax mechanism is incompletely characterized in Western literature. Russian publications describe:
GABA Modulation
Like Selank, modest GABAergic activity contributing to anxiolytic effects.
BDNF Upregulation
Reported to increase BDNF expression in rodent brain - mechanistic basis for putative neurotrophic claims.
Stress Resistance
Improved performance on stress-paradigm tests in rodents (forced swim, elevated plus maze).
Linear Peptide Stability
Linear short peptide; reasonably stable in storage. No Met or Cys residues - no GHK-Cu chemistry conflict.
Intranasal CNS Access
Like Selank/Semax, intranasal route enables direct nasal-to-brain transport bypassing the blood-brain barrier.
What to expect
Days 1-7: subtle anxiolytic onset.
Weeks 1-2: peak anxiolytic and putative neurotrophic effect.
Weeks 2-4: end of typical cycle; effects fade after discontinuation.
Evidence
Claims we could not support
No abstract we checked supports these for this molecule at this route. That is not the same as saying they are false — it marks where the evidence is missing.
Dose/route: 100-200 mcg per nostril intranasally 1-2x daily or SubQ. No checked PubMed/PMC abstract for Adamax peptide administration was found.
Mechanism. The PubMed search term resolved only to unrelated AdaMax optimizer papers; no peptide record with a usable abstract was found.
Primary safety concern. No human or animal PubMed abstract for the claimed peptide was found.
Side effects & safety
Commonly reported
- Mild nasal irritation (intranasal route)
- Mild headache (early doses)
- Possible mild sedation
Less common & notes
- Long-term safety not characterized in Western populations.
- Allergic reactions rare.
- Russian neuropeptide class has generally good safety profile in published literature but Western-grade safety data is limited.
Pharmacokinetics
Plasma
Post-dose
Functional
Intranasal preferred for CNS access
Per dose; cumulative effects over weeks
Renal/peptidase
Storage. Refrigerate. Reconstituted: 21-28 days.
Regulatory status
Not FDA-approved. Available in Russian Federation as research / OTC nutraceutical context. Western use is research-chemical only.
Put it to work
Calculate, log & track
Open Adamax straight into OnePin with your vial and dose pre-filled, then let it handle the syringe math and remind you before the vial runs out.
Open Adamax in the app →Go deeper
The guide & community
The complete Adamax walkthrough, real protocol discussion and coaching live inside the BlessUp community on Skool.
Join the community ↗